The Gut–Lung Microbiome Crosstalk and Pulmonary Disease
Biomolecules · 04.06.2026 · 16 (6) · 833
DOI: 10.3390/biom16060833 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 04.06.2026. Verfasst von Diren Beyoğlu und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Health Sciences, Western New England University, Springfield, MA 01119, USA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Lung, Lung Diseases, Microbiota. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 178 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Both the gut and the lungs possess a microbiome, a community of commensal bacteria, archaea, fungi, and viruses that perform important housekeeping functions in those organs. The colonic microbiome primarily ferments indigestible dietary fibers into essential short-chain fatty acids, synthesizes essential vitamins, regulates the mucosal immune system, and forms a protective barrier against pathogenic colonization. The lung microbiome maintains respiratory health primarily by regulating mucosal immunity, providing a physical barrier against invading pathogens, and producing beneficial metabolites. Several colonic microbiota metabolites, including the short-chain fatty acids acetate, propionate, and butyrate, together with the tryptophan metabolites indole-3-acetate and indole-3-propionate, secondary bile acids, and the polyamines spermidine and putrescine, are transported to the lungs via the gut–lung axis. These colonic microbiota biomolecules suppress lung inflammation, strengthen immune homeostasis, and reduce the severity of respiratory diseases. In contrast, lung microorganisms and their metabolites can travel to the gut via the gut–lung axis, influencing intestinal immune responses and potentially leading to an imbalance of gut microorganisms or dysbiosis. This means that respiratory diseases may lead to digestive issues, intestinal inflammation and chronic diseases. Here, we have reviewed this crosstalk and its impact on the principal pulmonary diseases: asthma, chronic obstructive pulmonary disease, cystic fibrosis, bronchogenic carcinoma, COVID-19, interstitial lung diseases, pneumonia, and tuberculosis. It is concluded that the gut microbiome plays a significant part in lung health and disease. Diet, tobacco smoking and electronic cigarette vaping all impact both the gut and lung microbiomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy and Health Sciences, Western New England University, Springfield, MA 01119, USA.
ORCID-Profile: Diren Beyoğlu, Jeffrey R Idle
Zitieren
APA
Beyoğlu, D., & Idle, J. R. (2026). The Gut–Lung Microbiome Crosstalk and Pulmonary Disease. Biomolecules, 16(6), 833. https://doi.org/10.3390/biom16060833
Vancouver
Beyoğlu D, Idle JR. The Gut–Lung Microbiome Crosstalk and Pulmonary Disease. Biomolecules. 2026;16(6):833. doi:10.3390/biom16060833
BibTeX
@article{Beyolu2026,
author = {Beyoğlu, Diren and Idle, Jeffrey R},
title = {The Gut–Lung Microbiome Crosstalk and Pulmonary Disease},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {6},
pages = {833},
doi = {10.3390/biom16060833}
}
EUVIMED